Bruker (BRKR) Wells Fargo 21st Annual Healthcare Conference summary

Strategic initiatives and technology integration

• Reorganization created the BioSpin Group, integrating NMR and mass spectrometry for advanced structural biology and drug discovery applications.

• NMR, combined with mass spectrometry and other technologies, is positioned as essential for deep phenome-level data and AI model training.

• Acquisition of MIMETAS (90% stake) expands into humanized microphysiological systems, enhancing multi-omics and spatial biology capabilities.

• MIMETAS business, currently ~€10M, is expected to grow to €50–100M over several years, driven by consumables and aftermarket sales.

• Strategic focus on automated, digitized labs and AI-driven workflows, supported by Chemspeed and Atinary partnerships.

Financial performance and outlook

• EPS outperformed expectations, aided by tariff recovery and cost-saving actions, with strong operating margin improvement.

• Book-to-bill ratio exceeded 1x for the fourth consecutive quarter; organic order growth surpassed 10% year-over-year.

• China orders rose over 20% in Q2, with broad strength across biopharma, academia, and semiconductors.

• Q4 is expected to be seasonally strong, with ultra-high field system deliveries and semi orders contributing to a projected 5% revenue step-up.

• Longer order-to-revenue cycles are attributed to complex, multi-year contracts, especially in deep tech and semiconductor metrology.

Deep tech and market expansion

• Deep tech portfolio includes semiconductor metrology (€300–500M), defense and aviation security, and energy research.

• Aviation security systems are expanding globally, with installations in major airports and growing market share.

• Energy research, including fusion projects, represents a €100M+ business with high growth and multi-year order visibility.

• Fusion research is in early stages, with significant investment and long-term demand for specialized superconducting materials.

• Collaborations with partners like Luvata aim to meet future demand for superconductors in fusion energy.